MA25653A1 - Derives d'amides heterocycliques. - Google Patents

Derives d'amides heterocycliques.

Info

Publication number
MA25653A1
MA25653A1 MA26757A MA26757A MA25653A1 MA 25653 A1 MA25653 A1 MA 25653A1 MA 26757 A MA26757 A MA 26757A MA 26757 A MA26757 A MA 26757A MA 25653 A1 MA25653 A1 MA 25653A1
Authority
MA
Morocco
Prior art keywords
derivatives
heterocyclic amides
amides
heterocyclic
Prior art date
Application number
MA26757A
Other languages
English (en)
Inventor
Stanley Poss Christopher
Frank Brown Matthew
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of MA25653A1 publication Critical patent/MA25653A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/08—Antibacterial agents for leprosy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40—Benzopyrazines
    • C07D241/44—Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Transplantation (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
MA26757A 2000-02-04 2002-08-01 Derives d'amides heterocycliques. MA25653A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US18015900P 2000-02-04 2000-02-04

Publications (1)

Publication Number Publication Date
MA25653A1 true MA25653A1 (fr) 2002-12-31

Family

ID=22659425

Family Applications (1)

Application Number Title Priority Date Filing Date
MA26757A MA25653A1 (fr) 2000-02-04 2002-08-01 Derives d'amides heterocycliques.

Country Status (37)

Country Link
US (2) US6548671B2 (fr)
EP (1) EP1252154A1 (fr)
JP (1) JP2003522164A (fr)
KR (2) KR20020072304A (fr)
CN (1) CN1398265A (fr)
AP (1) AP2002002595A0 (fr)
AR (1) AR027349A1 (fr)
AU (1) AU2699701A (fr)
BG (1) BG106922A (fr)
BR (1) BR0108002A (fr)
CA (1) CA2399214A1 (fr)
CZ (1) CZ20022542A3 (fr)
EA (2) EA200401099A1 (fr)
EE (1) EE200200432A (fr)
GE (1) GEP20043301B (fr)
GT (1) GT200100021A (fr)
HK (1) HK1050006A1 (fr)
HN (1) HN2001000021A (fr)
HR (1) HRP20020638A2 (fr)
HU (1) HUP0204560A3 (fr)
IL (1) IL150862A0 (fr)
IS (1) IS6468A (fr)
MA (1) MA25653A1 (fr)
NO (1) NO20023675L (fr)
NZ (1) NZ520075A (fr)
OA (1) OA12174A (fr)
PA (1) PA8511401A1 (fr)
PE (1) PE20011057A1 (fr)
PL (1) PL357094A1 (fr)
SK (1) SK10882002A3 (fr)
SV (1) SV2002000302A (fr)
TN (1) TNSN01021A1 (fr)
TW (1) TW200804311A (fr)
UA (1) UA72789C2 (fr)
UY (1) UY26568A1 (fr)
WO (1) WO2001057023A1 (fr)
ZA (1) ZA200206140B (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002347985A1 (en) 2001-11-15 2003-06-10 Eli Lilly And Company Peroxisome proliferator activated receptor alpha agonists
SE0201980D0 (sv) * 2002-06-24 2002-06-24 Astrazeneca Ab Novel compounds
US20040097554A1 (en) * 2002-10-30 2004-05-20 Pfizer Inc Heteroaryl-hexanoic acid amide derivatives as immonomodulatory agents
US20040087571A1 (en) * 2002-10-30 2004-05-06 Pfizer Inc Methods of using CCR1 antagonists as immunomodulatory agents
WO2007059219A1 (fr) * 2005-11-15 2007-05-24 Vertex Pharmaceuticals Incorporated Azaindazoles utiles en tant qu'inhibiteurs de kinases
CN1971279B (zh) * 2006-12-06 2011-05-18 华中农业大学 喹噁啉-2-羧酸残留的酶联免疫检测方法及试剂盒
SG11201906627YA (en) 2017-03-13 2019-08-27 Raqualia Pharma Inc Tetrahydroquinoline derivatives as p2x7 receptor antagonists

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL88619A0 (en) * 1987-12-15 1989-07-31 Pfizer Non-peptidic renin inhibitors
EP0374098A3 (fr) * 1988-12-15 1991-05-02 Ciba-Geigy Ag Inhibiteurs de protéase rétrovirale
JPH06510766A (ja) 1991-09-11 1994-12-01 スミスクライン・ビーチャム・コーポレイション Ｈ．ｉ．ｖ．阻害剤としてのヘテロ環含有ペプチド同配体
WO1993017003A1 (fr) * 1992-02-26 1993-09-02 Smithkline Beecham Corporation Inhibiteurs de la protease retrovirale
ATE220661T1 (de) * 1994-10-19 2002-08-15 Novartis Erfind Verwalt Gmbh Antivirale ether von aspartat-protease-substrat- isosteren
US6403587B1 (en) * 1997-02-26 2002-06-11 Pfizer Inc. Heteroaryl-hexanoic acid amide derivatives, their preparation and their use as selective inhibitors of MIP-1-α binding to its CCR 1 receptor
ATE337307T1 (de) * 1998-02-05 2006-09-15 Pfizer Prod Inc Neue dihydroxyhexansäurederivate

Also Published As

Publication number Publication date
ZA200206140B (en) 2003-08-01
AR027349A1 (es) 2003-03-26
US6689886B2 (en) 2004-02-10
UY26568A1 (es) 2001-08-27
WO2001057023A1 (fr) 2001-08-09
KR20050009776A (ko) 2005-01-25
NO20023675D0 (no) 2002-08-02
OA12174A (en) 2006-05-09
NO20023675L (no) 2002-09-10
BG106922A (en) 2003-03-31
PA8511401A1 (es) 2002-09-17
HUP0204560A3 (en) 2005-03-29
KR20020072304A (ko) 2002-09-14
AU2699701A (en) 2001-08-14
CZ20022542A3 (cs) 2003-08-13
HUP0204560A2 (en) 2003-05-28
CA2399214A1 (fr) 2001-08-09
UA72789C2 (en) 2005-04-15
BR0108002A (pt) 2002-10-29
EA200401099A1 (ru) 2005-02-24
US20030204086A1 (en) 2003-10-30
EA005320B1 (ru) 2005-02-24
GEP20043301B (en) 2004-02-10
HN2001000021A (es) 2001-07-08
US6548671B2 (en) 2003-04-15
EE200200432A (et) 2003-12-15
CN1398265A (zh) 2003-02-19
NZ520075A (en) 2004-02-27
IS6468A (is) 2002-07-11
SK10882002A3 (sk) 2003-10-07
HRP20020638A2 (en) 2004-12-31
GT200100021A (es) 2001-01-31
TNSN01021A1 (fr) 2005-11-10
TW200804311A (en) 2008-01-16
PL357094A1 (en) 2004-07-12
IL150862A0 (en) 2003-02-12
HK1050006A1 (zh) 2003-06-06
AP2002002595A0 (en) 2002-09-30
SV2002000302A (es) 2002-07-16
JP2003522164A (ja) 2003-07-22
US20020132810A1 (en) 2002-09-19
PE20011057A1 (es) 2001-10-22
EA200200749A1 (ru) 2002-12-26
EP1252154A1 (fr) 2002-10-30

Similar Documents

Publication Publication Date Title
FR20C1039I2 (fr) Derives de l'uk-2a
MA26932A1 (fr) Derives d'imidazole.
MA26816A1 (fr) Derives d'amino-triazolopyridine
FR15C0086I2 (fr) Derives d'hydroxamate en tant qu'inhibiteurs de desacetylase
MA27083A1 (fr) Derives de nicotine ou d'isonicotine benzothiazole
AR028567A1 (es) Nuevos derivados de fenil-propargileter
NO20040198L (no) Dolastatin 10 derivater
DE60134338D1 (de) Piperazin-derivate
MA26831A1 (fr) Derives de benzodiazepine."
MA27126A1 (fr) 3'PROMEDICAMENTS DE 2'-DESOXY- β-L-NUCLEOSIDES
NO20022095D0 (no) Heterocyklisk substituerte pyrazoloner
AR028596A1 (es) Nuevos derivados de fenilglicina
AR028280A1 (es) Derivados de 2-amino-3-(alquil)-pirimidona
FR2806720B1 (fr) Derives de 2,2,6,6-diethyl-dimethyl-1-alcoxypiperidines et 1-oxydes correspondants
DK1198453T3 (da) N-(indolcarbonyl-)piperazinderivater
PT1000048E (pt) Derivados substituidos do 1,2,3,4-tetrahidronaftaleno
AR028281A1 (es) Derivados de 2-(arilalquilamino) pirimidona y derivados de 2-(heteroaroarilalquilamino) pirimidona
DE50107988D1 (de) Substituierte 1,2,3,4-tetrahydrochinolin-2-carbonsäurederivate
AR028607A1 (es) Derivados de 1,4-diazepan-2,5-diona
MA26941A1 (fr) Nouveaux derives d'aminocyclohexane
PT1322592E (pt) Derivados substituidos de 1-aminobutan-3-ol
MA25653A1 (fr) Derives d'amides heterocycliques.
NO20030868L (no) N-(3,5-diklor-2-metoksyfenyl)-4-metoksy-3-piperazin-1-yl- benzensulfonamid
MA27240A1 (fr) Derives d'imidazoquinoleine
DE60031450D1 (de) Polymorph v von torasemid